In Canada, it is estimated that endometrial and ovarian cancers affect approximately 10,000 Canadian women per year. And yet, cure rates haven’t improved in over 30 years. A breakthrough led by the MUHC’s Dr. Lucy Gilbert promises to radically reduce this threat to women’s lives.
The DOvEEgene test is a minimally invasive test that can detect cancer using DNA analysis before it becomes a death sentence. Dr. Gilbert and her team have now begun the final clinical trial of this lifesaving test. Their goal is to make the DOvEEgene test a routine part of women’s health, just like the pap smear.
This is the third and last phase of the DOvEE project, which started in 2008 and has helped thousands of women to recognize ovarian and endometrial cancer symptoms.
GENERAL ENQUIRIES
MEDIA ENQUIRIES
OFFICE HOURS
| MON-FRI | 8:30 am – 4:30 pm |
| Saturday | Closed |
| Sunday | Closed |
